- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Medipattern ships B-CAD to China
Other headlines:Dunlee improves CT tube offering
Medipattern ships B-CAD to China
Canadian software developer Medipattern has shipped the first 10 of 200 B-CAD breast screening ultrasound packages ordered by the China Primary Health Care Foundation. The software product automatically creates standardized worksheets and reports that assist in the detection of breast cancer. The 200 units will serve as the foundation for a pilot breast-screening program in rural Chinese hospitals. Training in their use was scheduled to begin by the end of this month in Beijing.
Dunlee improves CT tube offering
Dunlee has upgraded its replacement tube for the installed base of GE BrightSpeed 16 Elite, BrightSpeed 8 Edge, and BrightSpeed 4 Excel CT scanners. The new tube features an improved mounting plate and warranty identical to the one offered by GE on its own tube, according to Dunlee, covering 12 months or 6000 patient exams.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
